BRCA1 and cancer: In this context it is important to distinguish between pathogenic variations in the well-established actionable genes such as BRCA1 and BRCA2 and novel candidate genes such as FANCM and BLM. Of note, we could classify about haft of the variants as having either likely or possible clinical significance for the cancer; however, with the caution that further validation is needed to confirm these potential causalities, including pedigree of affected families and functional studies of variants.